ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
P/B ratio for ESSA Pharma Inc. (EPIX)
P/B ratio as of 2023: 0.94
According to ESSA Pharma Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.94. At the end of 2022 the company had a P/B ratio of 0.48.
P/B ratio history for ESSA Pharma Inc. from 2012 to 2023
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2023 | 0.94 |
| 2022 | 0.48 |
| 2021 | 1.59 |
| 2020 | 1.95 |
| 2019 | 0.58 |
| 2018 | 1.57 |
| 2017 | -1.97 |
| 2016 | -137.78 |
| 2015 | 26.15 |
| 2014 | 35.12 |
| 2013 | 144.68 |
| 2012 | 49.54 |